# Stryker (SYK) Q2 2026 earnings

Results filed 2026-07-30 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/syk/2026-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/310764/000031076426000048/0000310764-26-000048-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Stryker is recovering from a cyber incident that disrupted supply and left backorders, while Mako installations hit a record Q2 and Triathlon Gold moves toward full commercial launch.

Stryker's quarter was shaped by its recovery from the cybersecurity incident first reported on March 11, 2026. Production ramped back up, but the supply disruption left a meaningful backorder situation and lost sales. Even so, sales grew on higher unit volume across MedSurg and Neurotechnology and Orthopaedics, and Stryker delivered its best ever Q2 for Mako installations.
Management says it enters the second half with regained momentum and wants to keep growing at the high end of MedTech. The plan leans on a steady cadence of innovation, including the move to full commercial launches of Triathlon Gold. The main tension is supply: demand is described as strong, so clearing backorders and avoiding further disruption matters most.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Net sales | $6,589 | up 9.4% from a year ago | GAAP |
| Net earnings | $1,276 | up 44.3% from a year ago | GAAP |
| Reported diluted EPS | $3.30 | up 44.1% from a year ago | GAAP |
| Adjusted diluted EPS | $3.69 | up 17.9% from a year ago | non-GAAP |
| Gross profit margin | 68.3% |  | GAAP |
| Operating income | $1,659 | up 49.1% from a year ago | GAAP |
| Operating income margin | 25.2% |  | GAAP |
| Adjusted operating income margin | 27.4% | up 170 bps from a year ago | non-GAAP |
| Operating cash flow (six months) | $1,842 | up from $1,361 million in the first six months of 2025 | GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| MedSurg and Neurotechnology | $3,625 | up 9.7% as reported |
| Orthopaedics | $2,964 | up 9.1% as reported |
| Medical | $1,122 | up 13.4% as reported |
| Endoscopy | $1,004 | up 11.7% as reported |
| Instruments | $1,003 | up 9.3% as reported |
| Vascular | $496 | down 0.7% as reported |
| Trauma and Extremities | $1,072 | up 11.9% as reported |
| Knees | $693 | up 8.4% as reported |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Organic net sales growth | full year 2026 | 8.3% to 9.3% |
| Adjusted net earnings per diluted share | full year 2026 | $14.95 to $15.10 |

## Key takeaways

1. **Cyber incident recovery drove supply and sales** Production ramped as recovery continued, but the supply disruption created a meaningful backorder situation with lost sales in the quarter. Restoring supply is the main near-term operating task.
2. **Mako had its best ever Q2 installations** Stryker focused more on competitive users than on existing Stryker users in these installations, which suggests the robot is winning share from rivals rather than only expanding inside its base.
3. **Triathlon Gold is moving to full commercial launch** Management said it is rapidly moving to full commercial launches of Triathlon Gold, extending its knee portfolio, where Knees sales grew 8.4% in the quarter.
4. **Demand is not the constraint, backlog is** Management said orders are already there and that there have been zero cancellations in its books. Backordered demand remains to be fulfilled as supply recovers.
5. **New competitors are limited to part of the market** Management said some new competitors tend to be more in just the aspiration portion of the market. Stryker is therefore not seeing broad competitive pressure across its robotic offering.

## Questions

**How did the cyber incident affect Stryker's business this quarter?** Stryker's recovery continued as it ramped overall production, but the supply disruption resulted in a meaningful backorder situation with lost sales. Management said it made significant progress in recovering and enters the second half with regained momentum.
**How is Mako performing?** Stryker delivered its best ever Q2 for Mako installations. It focused more on competitive users than existing Stryker users.
**Is demand for Stryker's products healthy?** Management said orders are already there, so demand is not the problem, and it has seen zero cancellations in its books. Organic sales growth came from increased unit volume.
**What new products is Stryker launching?** Stryker said it is rapidly moving to full commercial launches of Triathlon Gold. The sources give no further detail on launch timing.
**Is Stryker facing new competition?** Management said there are some new competitors, which tend to be more in just the aspiration portion of the market. Stryker also faces pricing pressure and changes in the competitive environment as listed risks.

## Slides and investor documents

- [Webcast](https://stryker-2q2026-earnings.open-exchange.net) (Webcast replay)
- [Form 10-Q](https://s22.q4cdn.com/857738142/files/doc_financials/2026/q2/syk10q6302026.pdf) (Document)

